Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study

Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study

Objective: Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19 infections, and cytokine storm is associated with disease severity. Tocilizumab, an interleukin-6 receptor antagonist, is used to treat chimeric antigen receptor T cell-induced cytokine release syndrome and may...

Full description

Bibliographic Details
Main Authors: Edmund Huang, Sharon Isonaka, Haoshu Yang, Erin Salce, Elisa Rosales, Stanley C. Jordan
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:International Journal of Infectious Diseases
Subjects:
COVID-19
Tocilizumab
SARS-CoV2
Acute respiratory distress syndrome
Cytokine release syndrome
Pneumonia
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221001430

Internet

http://www.sciencedirect.com/science/article/pii/S1201971221001430

Similar Items